Cambridge, MA – Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology ...

Artificial intelligence is rapidly transforming the pharmaceutical industry, dramatically reducing the time and cost required to develop new medicines before they ever reach human testing, according ...